
Quarterly report 2025-Q3
added 11-06-2025
LENSAR Cash Flow 2011-2026 | LNSR
Annual Cash Flow LENSAR
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-2.28 M | -9.66 M | -14.9 M | -8.97 M | -13.8 M | -12.6 M | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
2.96 M | 2.42 M | 2.26 M | 1.52 M | 1.31 M | 2.64 M | - | - | - | - | - | - | - | - |
Accounts Payables |
6 M | 4.01 M | 5.42 M | 2.69 M | 2.48 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
6.08 M | 4 M | 6.04 M | 4.64 M | 2.01 M | - | - | - | - | - | - | - | - | - |
Total Inventories |
11.4 M | 15.7 M | 11.7 M | 6.49 M | 13.5 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow LENSAR
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -6.94 M | - | - | - | -5.31 M | - | - | - | -6.7 M | - | -10.1 M | -5.4 M | -2.61 M | - | -8.23 M | -6.08 M | -4.62 M | - | -11.8 M | -11.7 M | -6.36 M | - | -5.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
229 K | 230 K | 844 K | - | 232 K | 232 K | 647 K | - | 273 K | 275 K | 578 K | - | 276 K | 287 K | 541 K | - | 1.06 M | 670 K | 328 K | - | 1.04 M | 808 K | 477 K | - | 2.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
14.8 M | 11.3 M | 7.75 M | 6 M | 3.87 M | 4.12 M | - | 4.01 M | 3.94 M | 4.62 M | 4.92 M | 5.42 M | 3.51 M | 4.19 M | 2.85 M | 2.69 M | 2.4 M | 2.86 M | 1.7 M | 2.48 M | 2.48 M | 2.48 M | 2.48 M | 1.58 M | 1.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
5.9 M | 4.99 M | 6.88 M | 6.08 M | 4.37 M | 5.89 M | - | 4 M | 3.85 M | 3.22 M | 4.66 M | 6.04 M | 3.56 M | 2.76 M | 3.58 M | 4.64 M | 2.8 M | 2.7 M | 2.1 M | 2.01 M | 2.01 M | 2.01 M | 2.01 M | 3.38 M | 3.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
20.6 M | 19.2 M | 15.3 M | 11.4 M | 14.9 M | 17.9 M | - | 15.7 M | 17.5 M | 18.2 M | 15.7 M | 11.7 M | 7.89 M | 5.86 M | 4.28 M | 6.49 M | 10.2 M | 12.4 M | 13 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 8.06 M | 8.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company LENSAR, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Delcath Systems
DCTH
|
$ 9.19 | 2.28 % | $ 329 M | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Helius Medical Technologies
HSDT
|
$ 2.14 | 6.47 % | $ 1.3 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 9.54 | - | $ 735 M | ||
|
Inogen
INGN
|
$ 6.41 | 1.42 % | $ 171 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.33 | -1.48 % | $ 21.5 M | ||
|
IRadimed Corporation
IRMD
|
$ 101.59 | 0.62 % | $ 1.29 B | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
LivaNova PLC
LIVN
|
$ 63.64 | 1.99 % | $ 3.47 B | ||
|
CONMED Corporation
CNMD
|
$ 37.07 | 1.38 % | $ 1.15 B | ||
|
NanoVibronix
NAOV
|
- | - | $ 1.08 M | ||
|
Electromed
ELMD
|
$ 24.71 | 0.02 % | $ 209 M | ||
|
Medtronic PLC
MDT
|
$ 87.73 | 1.33 % | $ 113 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
MiMedx Group
MDXG
|
$ 4.11 | -0.61 % | $ 607 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.67 | -4.18 % | $ 36.5 M | ||
|
Aethlon Medical
AEMD
|
$ 2.38 | 10.12 % | $ 3.71 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Orthofix Medical
OFIX
|
$ 11.86 | 1.19 % | $ 470 M | ||
|
InspireMD
NSPR
|
$ 1.76 | -1.68 % | $ 113 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 11.37 | -1.0 % | $ 1.54 B | ||
|
Penumbra
PEN
|
$ 336.27 | 0.63 % | $ 13.1 B | ||
|
Myomo
MYO
|
$ 0.69 | -0.83 % | $ 28.9 M | ||
|
Insulet Corporation
PODD
|
$ 217.14 | -3.71 % | $ 15.3 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 2.3 | -4.38 % | $ 135 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.72 | -4.86 % | $ 139 M | ||
|
Profound Medical Corp.
PROF
|
$ 5.9 | 14.47 % | $ 180 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 16.33 | 2.64 % | $ 383 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.9 | 2.09 % | $ 166 M | ||
|
Outset Medical
OM
|
$ 3.49 | -1.13 % | $ 53.1 K |